SkyePharma rocked by regulatory delay
Drugs developer SkyePharma was sailing close to its 52-week low after it announced another regulatory delay for its asthma treatment, Flutiform.
Drugs developer SkyePharma was sailing close to its 52-week low after it announced another regulatory delay for its asthma treatment, Flutiform.
The decentralised procedure (DCP) for the regulatory review of Flutiform has been referred to the European Medicines Agency and its Committee for Medicinal Products for Human Use for arbitration, after it proved impossible to get a complete consensus on whether the drug should be approved for use in Europe, even after deliberations by "concerned member states" went into extra time.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
SkyePharma and its authorised distributor for Flutiform, Mundipharma, are confident in the efficacy and safety profile of Flutiform, which they say is supported by the clinical evidence.
The Marketing Authorisation Application for Flutiform consisted of a substantial package of data including the results of eight phase I/II studies and nine Phase III studies conducted in a population of 4,500 patients, of which more than 1,900 patients received Flutiform.
"Although this regulatory delay is disappointing for SkyePharma and potential patients we remain confident in the efficacy and safety profile of Flutiform and will continue to work closely with our partner, Mundipharma, to seek its approval in Europe as soon as possible," said Dr. Axel Mller, Chief Executive Officer of SkyePharma.
Industry sources suggested the arbitration process could take six to nine months.
The shares fell 7.25p to 32p on the news.
--
jh
-
Best places to live in England and Wales in 2026 – and how much they costCriteria like value for money, natural beauty, good schools, jobs and a high quality of life are key for those looking at areas to buy a house – but how much will it cost you to live in a high ranking town or city? We reveal the best places to live in England and Wales.
-
London house prices: Is the capital's property boom over?Buyers and investors have always been drawn towards the capital’s property market. But as house prices stall, is the market as lucrative as it once was and are buyers and investors still interested?
